Invivyd(NASDAQ) IVVD

Invivyd, Inc. makes medicine to protect people from serious viruses. These treatments help people with weak immune systems fight infections. The company uses antibodies to provide immediate protection against COVID-19.

A Focused Pipeline for Viral Protection

• PEMGARDA: Long-acting antibody therapy for preventing COVID-19 in immunocompromised patients; generated $28.0 million in net product revenue for the six months ended June 30, 2026.
• VYD2311: Next-generation antibody candidate for COVID-19 currently in Phase 3 clinical trials; designed for delivery via intramuscular or subcutaneous injections.
• VBY329: Preclinical antibody candidate intended to prevent respiratory syncytial virus (RSV) infections in infants and children.
• VMS063: Investigational antibody for measles that is moving toward regulatory submission for human clinical trials in the second half of 2026.

Strategic Steps and Clinical Progress

• Received Emergency Use Authorization from the Food and Drug Administration (FDA) for PEMGARDA in March 2024.
• Completed enrollment in the upsized Phase 3 DECLARATION clinical trial for VYD2311 in June 2026 with approximately 2,400 participants.
• Formed the SPEAR Study Group in July 2025 to guide research for treatments targeting Long COVID and vaccine injury.
• Launched the Antibodies for Any Body national education campaign in April 2026 to increase public understanding of immune health.
• Announced alignment with the FDA in August 2025 on a rapid approval pathway for VYD2311.

How the Company Navigates Viral Shifts

Invivyd uses a proprietary technology platform to find and develop monoclonal antibodies (mAbs) that stay effective as viruses change. The company also maintains an industrial virology system to test its treatments against new viral variants in real time.

Financial Realities and Operations

• Product revenue, net reached $14.3 million for the three months ended June 30, 2026.
• Net loss was $85.8 million for the six-month period ended June 30, 2026.
• Market capitalization reached $279.5 million in Q2 2026, up 225.8% year over year.
• Cash and cash equivalents totaled $160.1 million as of June 30, 2026.
• Invivyd concluded there is substantial doubt about its ability to continue as a going concern beyond one year from the June 30, 2026 financial report issuance.

Evolution of a Viral Therapy Company

Invivyd is transitioning from a research-focused organization to a commercial company with authorized treatments and a growing clinical pipeline. It continues to adapt its technology to address evolving viral threats like COVID-19, measles, and respiratory syncytial virus.